This company has been marked as potentially delisted and may not be actively trading. (ANTX) (ANTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesTrendsBuy This Stock ANTX vs. PROC, OPTN, VIRI, VHAQ, PYRGF, OSTX, AADI, ATNM, NBRV, and EGRXShould you be buying (ANTX) stock or one of its competitors? The main competitors of (ANTX) include Procaps Group (PROC), OptiNose (OPTN), Virios Therapeutics (VIRI), Viveon Health Acquisition (VHAQ), PyroGenesis Canada (PYRGF), OS Therapies (OSTX), Aadi Bioscience (AADI), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical preparations" industry. (ANTX) vs. Its Competitors Procaps Group OptiNose Virios Therapeutics Viveon Health Acquisition PyroGenesis Canada OS Therapies Aadi Bioscience Actinium Pharmaceuticals Nabriva Therapeutics Eagle Pharmaceuticals Procaps Group (NASDAQ:PROC) and (ANTX) (NYSE:ANTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings. Is PROC or ANTX more profitable? Procaps Group's return on equity of 0.00% beat (ANTX)'s return on equity.Company Net Margins Return on Equity Return on Assets Procaps GroupN/A N/A N/A (ANTX) N/A -57.62%-52.08% Do analysts prefer PROC or ANTX? (ANTX) has a consensus price target of $1.50, suggesting a potential upside of 39.02%. Given (ANTX)'s stronger consensus rating and higher possible upside, analysts plainly believe (ANTX) is more favorable than Procaps Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Procaps Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00(ANTX) 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, PROC or ANTX? Procaps Group has a beta of -0.05, suggesting that its stock price is 105% less volatile than the S&P 500. Comparatively, (ANTX) has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Does the media favor PROC or ANTX? In the previous week, Procaps Group's average media sentiment score of 0.00 equaled (ANTX)'saverage media sentiment score. Company Overall Sentiment Procaps Group Neutral (ANTX) Neutral Do insiders & institutionals hold more shares of PROC or ANTX? 90.5% of (ANTX) shares are held by institutional investors. 19.9% of Procaps Group shares are held by insiders. Comparatively, 20.8% of (ANTX) shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has stronger earnings & valuation, PROC or ANTX? Procaps Group has higher revenue and earnings than (ANTX). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProcaps Group$409.92M0.26$42.54MN/AN/A(ANTX)N/AN/A-$64.73M-$2.04-0.53 Summary(ANTX) beats Procaps Group on 6 of the 10 factors compared between the two stocks. Get (ANTX) News Delivered to You Automatically Sign up to receive the latest news and ratings for ANTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANTX vs. The Competition Export to ExcelMetric(ANTX)Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$33.76M$790.73M$5.54B$20.72BDividend YieldN/A4.84%5.24%3.72%P/E Ratio-0.531.3527.4328.09Price / SalesN/A226.97420.9838.30Price / CashN/A23.4436.8922.53Price / Book0.266.298.044.58Net Income-$64.73M-$27.73M$3.18B$986.06M (ANTX) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANTX(ANTX)N/A$1.08-11.6%$1.50+39.0%-60.2%$33.76MN/A-0.53N/APROCProcaps GroupN/A$0.95-40.3%N/A-62.0%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeOPTNOptiNose0.7551 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190VIRIVirios TherapeuticsN/A$4.76-2.9%$5.00+5.0%+1,899.2%$91.67MN/A-17.635VHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumePYRGFPyroGenesis Canada0.0904 of 5 stars$0.33-3.4%N/A-36.9%$62.17M$9.14M-5.5590OSTXOS Therapies2.6581 of 5 stars$1.85+8.8%$18.00+873.0%N/A$51.98MN/A-2.15N/ANews CoverageGap UpAADIAadi Bioscience0.6545 of 5 stars$2.09+2.0%$1.67-20.3%+42.1%$51.62M$25.07M-0.9240News CoverageHigh Trading VolumeATNMActinium Pharmaceuticals2.7412 of 5 stars$1.57+3.0%$4.00+155.6%N/A$48.82M$81K-1.1330NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070EGRXEagle PharmaceuticalsN/A$2.79-3.0%N/A-45.5%$36.23M$257.55M0.00100Gap Down Related Companies and Tools Related Companies PROC Competitors OPTN Competitors VIRI Competitors VHAQ Competitors PYRGF Competitors OSTX Competitors AADI Competitors ATNM Competitors NBRV Competitors EGRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (ANTX) Please log in to your account or sign up in order to add this asset to your watchlist. Share (ANTX) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANTX Stock Alerts